This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.


This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.


This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

Digital Health Solutions

As an increasing number of people worldwide are living with diabetes, our device and digital therapeutic innovations have the potential to support diabetes management.1-3
Digital Partnerships

In collaboration with partners we aim to close the loop to enable diabetes management through informed conversations.
Time in Range Thumbnail

Time in Range is a new clinical metric within diabetes management that complements HbA1c providing a more complete picture of daily glucose levels.4

ATTD 2024 took place on 6-9 March 2024 in Florence, Italy and online. The focus of the ATTD 2024 meeting was to spotlight innovative technologies and treatments in diabetes management.

The International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) was founded in 2008. Since then, 17 annual meetings have taken place.

ATTD brings together developers of new technology, diabetes professionals, researchers, industry stakeholders, start-ups, investors, regulatory authorities and those living with diabetes.


IDF. Diabetes Atlas, 9th Edition.


Klonoff DC et al. JDiabetes SciTechnol. 2018;12(3):551-553.


Peter Adolfsson et al. Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. DIABETES TECHNOLOGY & THERAPEUTICS Volume 22, Number 10, 2020.


Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care 2019;42(8):1593–1603